Physicians, patients and politicians had been consistently calling for the drug to be made available in Ireland under the HSE in the years since the European Medicines Agency's approval. Photograph: Rui Vieira/PAThe drug, called abemaciclib, will be given to people with high-risk oestrogen-driven breast cancer. Abemaciclib is a tablet and is given for two years to eligible patients, in combination with endocrine therapy.
The drug, from pharmaceutical business Eli Lilly and Company, was given initial market authorisation in 2018 for the treatment of metastatic breast cancer, with theIn pictures: Switzerland’s Nemo takes Eurovision 2024 crown as Ireland’s Bambie Thug comes sixthFamily withdraws Trinity bursary in protest over college becoming ‘no-go zone for Jews’made a recommendation to the HSE that it should “consider funding abemaciclib if its cost effectiveness can be improved”.
Prof Stephen Johnston, consultant medical oncologist and head of the breast unit at the Royal Marsden NHS Foundation Trust, as well as lead investigator for the trial on the effectiveness of the drug for early breast cancer patients, said abemaciclib is a “significant breakthrough”.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: IrishMirror - 🏆 4. / 98 Read more »